Skip to main content
Year archive

Purple Biotech Ltd. — 2024 filings

All 101 regulatory filings released by Purple Biotech Ltd. (PPBT) in 2024, sourced directly from the official regulator.

101 Filings
2024 Period
2024 filings (101)
Filing Released Lang
Purple Biotech Corporate Presentation December 2024
Investor Presentation
2024-12-07 English
Purple Biotech Corporate Presentation December 2024
Investor Presentation
2024-12-07 English
Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Regulatory Filings
2024-12-05 English
Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Report Publication Announcement
2024-12-05 English
6K: Transaction documents
Regulatory Filings
2024-12-04 English
6K: Transaction documents
Report Publication Announcement
2024-12-04 English
PROSPECTUS SUPPLEMENT-472,668 American Depositary Shares
Capital/Financing Update
2024-12-04 English
PROSPECTUS SUPPLEMENT-472,668 American Depositary Shares
Capital/Financing Update
2024-12-04 English
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
Capital/Financing Update
2024-12-03 English
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
Share Issue/Capital Change
2024-12-03 English
6K- Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
Regulatory Filings
2024-12-02 English
6K- Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
Report Publication Announcement
2024-12-02 English
Reports Third Quarter 2024 Financial Results
Earnings Release Q3 2024
2024-11-16 English
Reports Third Quarter 2024 Financial Results
Report Publication Announcement
2024-11-16 English
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
Regulatory Filings
2024-11-04 English
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
Report Publication Announcement
2024-11-04 English
6K: Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Regulatory Filings
2024-10-26 English
6K: Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Regulatory Filings
2024-10-26 English
6K: Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Regulatory Filings
2024-10-10 English
6K: Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Report Publication Announcement
2024-10-10 English
6K:Purple Biotech Corporate Presentation October 2024
Investor Presentation
2024-10-09 English
6K:Purple Biotech Corporate Presentation October 2024
Report Publication Announcement
2024-10-09 English
received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC
Regulatory Filings
2024-10-05 English
received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC
Regulatory Filings
2024-10-05 English
FORM 6-K- Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
Regulatory Filings
2024-09-18 English
FORM 6-K- Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
Report Publication Announcement
2024-09-18 English
6K:Purple Biotech Ltd Announces ADS Ratio Change
Regulatory Filings
2024-09-11 English
6K:Purple Biotech Ltd Announces ADS Ratio Change
Regulatory Filings
2024-09-11 English
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
Regulatory Filings
2024-09-10 English
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
Report Publication Announcement
2024-09-10 English
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
Regulatory Filings
2024-08-31 English
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
Regulatory Filings
2024-08-31 English
6K:Purple Biotech Corporate Presentation August 2024
Investor Presentation
2024-08-19 English
6K:Purple Biotech Corporate Presentation August 2024
Report Publication Announcement
2024-08-19 English
FORM 6-K-Second Quarter 2024 Financial Results and Business Highlights
Interim / Quarterly Report Q2 2024
2024-08-16 English
FORM 6-K-Second Quarter 2024 Financial Results and Business Highlights
Report Publication Announcement
2024-08-16 English
FORM 6-K -e results of the Annual General Meeting of Shareholders of the Company held on August 8, 2024
Declaration of Voting Results & Voting Rights Announcements
2024-08-08 English
FORM 6-K -e results of the Annual General Meeting of Shareholders of the Company held on August 8, 2024
Regulatory Filings
2024-08-08 English
Mr. Lior Fhima, who serves as the Company’s Chief Financial Officer, notified the Company of his resignation from such position , effective as of October 31, 2024.
Board/Management Information
2024-08-05 English
Mr. Lior Fhima, who serves as the Company’s Chief Financial Officer, notified the Company of his resignation from such position , effective as of October 31, 2024.
Board/Management Information
2024-08-05 English
PROSPECTUS - up to an aggregate of11,661,364 American Depositary Shares representing 116,613,640 Ordinary Shares
Share Issue/Capital Change
2024-07-31 English
PROSPECTUS - up to an aggregate of11,661,364 American Depositary Shares representing 116,613,640 Ordinary Shares
Capital/Financing Update
2024-07-31 English
Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
Regulatory Filings
2024-07-25 English
Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
Report Publication Announcement
2024-07-25 English
FORM F-1-ADS resale by the selling shareholders
Capital/Financing Update
2024-07-22 English
FORM F-1-ADS resale by the selling shareholders
Report Publication Announcement
2024-07-22 English
Corporate Presentation July 2024
Investor Presentation
2024-07-20 English
Corporate Presentation July 2024
Regulatory Filings
2024-07-20 English
FORM D-Notice of Exempt Offering of Securities
Regulatory Filings
2024-07-15 English
FORM D-Notice of Exempt Offering of Securities
Capital/Financing Update
2024-07-15 English
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
Regulatory Filings
2024-07-10 English
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
Report Publication Announcement
2024-07-10 English
PROSPECTUS SUPPLEMENT (To Prospectus Supplements Dated October 19, 2023 and June 23, 2020, to Prospectus dated December 13, 2019)
Capital/Financing Update
2024-07-03 English
PROSPECTUS SUPPLEMENT (To Prospectus Supplements Dated October 19, 2023 and June 23, 2020, to Prospectus dated December 13, 2019)
Capital/Financing Update
2024-07-03 English
6K: Inducement Offer to Exercise Existing Warrants to Purchase Ordinary Shares Represented by ADSs
Regulatory Filings
2024-07-03 English
6K: Inducement Offer to Exercise Existing Warrants to Purchase Ordinary Shares Represented by ADSs
Regulatory Filings
2024-07-03 English
6K-Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
Regulatory Filings
2024-07-03 English
6K-Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
Report Publication Announcement
2024-07-03 English
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
Regulatory Filings
2024-07-01 English
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
Report Publication Announcement
2024-07-01 English
Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
Regulatory Filings
2024-06-27 English
Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
Report Publication Announcement
2024-06-27 English
Immediate Report of Meeting To Be Held on August 8, 2024, PROXY STATEMENT
AGM Information
2024-06-26 English
Immediate Report of Meeting To Be Held on August 8, 2024, PROXY STATEMENT
Proxy Solicitation & Information Statement
2024-06-26 English
Immediate Report of Meeting To Be Held on August 8, 2024, PROXY STATEMENT
AGM Information
2024-06-26 English
Annual General Meeting of Shareholders will be held on Thursday, August 8 2024,PROXY STATEMENT
Proxy Solicitation & Information Statement
2024-06-26 English
Annual General Meeting of Shareholders will be held on Thursday, August 8 2024,PROXY STATEMENT
AGM Information
2024-06-26 English
6K: The Tel Aviv District Court dismissed the previously disclosed lawsuit and motion to approve the lawsuit as a class action lawsuit which was filed against us, our executive directors and certain o
Regulatory Filings
2024-06-20 English
6K: The Tel Aviv District Court dismissed the previously disclosed lawsuit and motion to approve the lawsuit as a class action lawsuit which was filed against us, our executive directors and certain o
Report Publication Announcement
2024-06-20 English
6K-Corporate Presentation June 2024
Investor Presentation
2024-06-05 English
6K-Corporate Presentation June 2024
Regulatory Filings
2024-06-05 English
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Regulatory Filings
2024-06-03 English
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Report Publication Announcement
2024-06-03 English
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Earnings Release Q2 2024
2024-06-01 English
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Report Publication Announcement
2024-06-01 English
First Quarter 2024 Financial Results and Provides Business Update
Earnings Release Q1 2024
2024-05-21 English
First Quarter 2024 Financial Results and Provides Business Update
Report Publication Announcement
2024-05-21 English
CORPORATE PRESENTATION
Investor Presentation
2024-05-04 English
CORPORATE PRESENTATION
Report Publication Announcement
2024-05-04 English
Purple Biotech’s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Regulatory Filings
2024-04-25 English
Purple Biotech’s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Report Publication Announcement
2024-04-25 English
FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Regulatory Filings
2024-03-30 English
FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Regulatory Filings
2024-03-30 English
to Present New Data On its Oncology Drug NT219 at AACR 2024
Regulatory Filings
2024-03-28 English
to Present New Data On its Oncology Drug NT219 at AACR 2024
Report Publication Announcement
2024-03-28 English
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Regulatory Filings
2024-03-14 English
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Report Publication Announcement
2024-03-14 English
Corporate Presentation March 2024
Investor Presentation
2024-03-06 English
Corporate Presentation March 2024
Report Publication Announcement
2024-03-06 English
FORM 20F FOR 2023
Annual Report FY 2023
2024-03-05 English
FORM 20F FOR 2023
Report Publication Announcement
2024-03-05 English
6K:Fourth Quarter and Full-Year 2023 Financial Results
Earnings Release FY 2023
2024-03-05 English
6K:Fourth Quarter and Full-Year 2023 Financial Results
Report Publication Announcement
2024-03-05 English
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
Regulatory Filings
2024-02-27 English
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
Report Publication Announcement
2024-02-27 English
6K: Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
Regulatory Filings
2024-02-13 English
6K: Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
Report Publication Announcement
2024-02-13 English
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
Regulatory Filings
2024-02-01 English
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
Report Publication Announcement
2024-02-01 English
Receipt of Nasdaq Minimum Bid Price Notification-6K
Regulatory Filings
2024-01-27 English
Receipt of Nasdaq Minimum Bid Price Notification-6K
Report Publication Announcement
2024-01-27 English